DelveInsight’s “Opioid Withdrawal Syndrome Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Opioid Withdrawal Syndrome, historical and forecasted epidemiology and the Opioid Withdrawal Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock key insights into the Opioid Withdrawal Syndrome Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Opioid Withdrawal Syndrome Market Size

 

Key Takeaways from the Opioid Withdrawal Syndrome Market Report

• In November 2024:- T. John Winhusen, PhD- The primary objective of this study is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and infant outcomes. The primary hypothesis is that the BUP-XR group will not have greater illicit opioid use than the BUP-SL group during pregnancy (non-inferiority).
• According to DelveInsight estimations, 9,077,124 Number of cases with long-term opioid usage were found in 2022 in the 7MM.
• As per DelveInsight’s estimations, the total number of cases with opioid withdrawal syndrome in the United States were approximately 7,087,561 in 2022 and are projected to decrease during the forecast period.
• According to DelveInsight’s estimates, the number of opioid misuse cases in EU4 and the UK were found to be approximately 1,365,293 in 2022.
• The leading Opioid withdrawal Syndrome Companies such as DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., and others.
• Promising Opioid withdrawal Syndrome Therapies such as Dexmedetomidine, Lofexidine, DMX-1002, BXCL501 (180 micrograms), Oxycodone, and others.

 

Stay ahead in the competitive landscape of the Opioid Withdrawal Syndrome Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Opioid Withdrawal Syndrome Treatment Market Size

 

Opioid Withdrawal Syndrome Epidemiology Segmentation in the 7MM

• Number of Opioid misuse cases
• Number of cases with long-term opioid usage
• Total Opioid Withdrawal Syndrome Cases

 

Download the report to understand which factors are driving Opioid Withdrawal Syndrome epidemiology trends @ Opioid Withdrawal Syndrome Prevalence

 

Opioid Withdrawal Syndrome Marketed Drugs

• LUCEMYRA (lofexidine hydrochloride): US World Meds LLC

LUCEMYRA is an oral, selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine. LUCEMYRA is not an opioid drug. While LUCEMYRA may lessen the severity of withdrawal symptoms, it may not completely prevent them and is only approved for treatment for up to 14 days. LUCEMYRA is not a treatment for OUD but can be used as part of a broader, long-term treatment plan for managing OUD. LUCEMYRA is under license from Britannia Pharmaceuticals, Ltd. USWM, LLC is the exclusive licensee and distributor of LUCEMYRA in the United States and Its territories.

 

Opioid Withdrawal Syndrome Emerging Drugs

• DMX-1002 (Ibogaine HCl): DemeRx IB, Inc. /atai Life Sciences

DMX-1002 is an oral formulation of ibogaine, an oneirogenic indole alkaloid with cholinergic, glutamatergic, and monoaminergic receptor modulatory activity. Ibogaine is a natural indole alkaloid derived from the West African iboga plant and has previously been marketed as a stimulant and antidepressant in France under the brand name Lambarène. Known for its oneirophrenic and hallucinogenic properties, uncontrolled data from hundreds of patients suggest that Ibogaine is effective as both an acute detoxifier and treatment for opioid addiction. At present, DMX-1002 is in Phase I/II of clinical development for the treatment of Opiate Withdrawal Syndrome. As per the DemeRx pipeline, the drug is being developed for opioid withdrawal management and relapse prevention, whereas as per atai Life Sciences pipeline, the drug is being developed for OUD treatment.

 

• MN-166: Medicinova

MN-166 is a first in class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves redirection of an approved drug, ibudilast, which was first approved in Japan more than 20 years ago.

 

Discover the future of Opioid Withdrawal Syndrome treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Opioid Withdrawal Syndrome Market Drivers and Barriers

 

Opioid Withdrawal Syndrome Market Outlook

The treatment approach for Opioid Withdrawal Syndrome depends on the severity of the symptoms experienced by the individual. In cases of mild withdrawal, patients are encouraged to prioritize hydration by consuming at least 2–3 L of water daily and may benefit from supplementation with vitamins B and C to support overall health. Typically, symptomatic treatment and supportive care suffice for managing mild symptoms, focusing on alleviating discomfort and ensuring the patient’s well-being during this phase.

 

Scope of the Opioid Withdrawal Syndrome Market Report

Coverage- 7MM

Study Period- 2020-2034

Opioid withdrawal Syndrome Companies- DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., and others.

Opioid withdrawal Syndrome Therapies such as Dexmedetomidine, Lofexidine, DMX-1002, BXCL501 (180 micrograms), Oxycodone, and others.

 

Explore the dynamics of the Opioid Withdrawal Syndrome Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Opioid Withdrawal Syndrome Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights

2. Report Introduction

3. Opioid Withdrawal Syndrome Market Overview at a Glance

4. Opioid Withdrawal Syndrome Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Opioid Withdrawal Syndrome: Disease Background and Overview

8. Opioid Withdrawal Syndrome Epidemiology and Patient Population

9. Patient Journey

10. Opioid Withdrawal Syndrome Marketed Drugs

11. Opioid Withdrawal Syndrome Emerging Drugs

12. Opioid Withdrawal Syndrome: Market Analysis

13. Key Opinion Leaders’ Views

14. Opioid Withdrawal Syndrome SWOT Analysis

15. Opioid Withdrawal Syndrome Unmet Needs

16. Opioid Withdrawal Syndrome Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market